Business
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the acceptance of two abstracts for poster present
About this update from X4 Pharmaceuticals, Inc.
[{"type":"image","alt":"X4 Pharmaceuticals","displaySize":"","headline":null,"caption":"X4 Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":140,"url":"https://media.zenfs.com/en/globenewswire.com/beb74090cc798d5c3771a2fadf409727"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sgkmhEK6I7T7bbBXoDPp1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/beb74090cc798d5c3771a2fadf409727","width":210,"height":140}},"lazy":false},{"type":"text","content":"Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor","length":119,"tagName":"p"},{"type":"text","content":"Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy","length":153,"tagName":"p"},{"type":"text","content":"BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the acceptance of two abstracts for poster presentation at the 30th Annual Congress of the European Hematology Association (EHA) taking place in Milan, Italy from June 12-15, 2025. The abstracts published online today summarize the clinical results from the company’s completed Phase 2 trial of mavorixafor in the treatment of certain primary chronic neutropenic (CN) disorders.","length":559,"tagName":"p"},{"type":"text","content":"“We are excited to present the positive data from our completed Phase 2 trial of chronic treatment of CN participants with mavorixafor to the global hematology community for the first time,” said Christophe Arbet-Engels, MD, PhD, Chief Medical Officer of X4 Pharmaceuticals. “With enrollment progressing in our ongoing pivotal Phase 3 trial in CN, we continue to look at these Phase 2 results as supportive of the design of the Phase 3 trial and a signal of its potential for success. Mavorixafor is the first innovation to be studied for the treatment of CN in more than 30 years and would be the first oral treatment available for this serious condition if approved.”","length":669,"tagName":"p"},{"type":"text","content":"Summary of EHA Posters to be Presented:The Phase 2 study of oral, once-daily mavorixafor was a six-month, open-label c...